

# **NEVADA 2024 HIV FAST FACTS**

Nevada Department of Health and Human services
Division of public and behavioral health
Office of HIV Prevention and Surveillance Program

Joe Lombardo, Governor, State of Nevada

Richard Whittley, MS, Director, Department of Health and Human Services

Dena Schmidt, Administrator, Division of Public and Behavioral Health

Ishan Azzam, PhD., MD., Chief Medical Officer, Division of Public and Behavioral Health









## **TABLE OF CONTENTS**

Purpose	3
Purpose	3
Data Considerations	3
Technical notes	3
Vocabulary Data Tables	4
Data Tables	5
Table 1. Nevada New HIV Diagnoses, 2024	
Table 2. Nevada New HIV Stage 3 (AIDS) Diagnoses, 2024	6
Table 3. Persons Living with HIV§ in Nevada, 2024	7
Table 5. Clark County New HIV Stage 3 (AIDS) Diagnoses, 2024	9
Table 6. Persons Living with HIV§ in Clark County, 2024	
Table 7 Washoe County New HIV Diagnoses, 2024	
Table 8. Washoe County New Stage 3 (AIDS) Diagnoses, 2024	
Table 9. Persons Living with HIV§ in Washoe County, 2024	
Table 10. All Other Counties New HIV Diagnoses, 2024	14
Table 11. All Other Counties A New HIV Stage 3 (AIDS) Diagnoses, 2024	15
Table 12. Persons Living with HIV§ in All Other Counties^, 2024	16
Table 13. Annual Percent Change: New HIV Diagnoses, Nevada, 2022-2024	17
Table 14. Annual Percent Change: Persons Living with HIV§ in Nevada, 2022-2024	
Table 15 Facility of Diagnosis for New HIV Diagnoses, Nevada, 2024	19
Table 16. Facility of Diagnosis for New Stage 3 (AIDS) Diagnoses, Nevada HIV, 2024	20



### **PURPOSE**

The primary purpose of the Nevada 2024 HIV Fast Facts report is to provide statistics and trends on HIV and HIV Stage 3 (AIDS) in Nevada. This annual publication is a reference document for policymakers, program managers, health planners, researchers, and community members who are concerned with the public health implications of this disease.

#### **METHODS**

The data used for this report is information gathered between January 1, 2024 to December 31, 2024 and was obtained from the enhanced HIV/AIDS Reporting System (eHARS) on March 9, 2025. Statistics provided in this publication are based on provisional data. The eHARS database application is provided by the Centers for Disease Control and Prevention (CDC) and is maintained by the Nevada Division of Public and Behavioral Health (DPBH) HIV Prevention and Surveillance Program (HPSP). The data is collected from medical laboratories, state and local health departments, and other community providers. The HIV case definition for this report utilizes the 2014 case definition. Per the CDC, an individual may be diagnosed concurrently with both HIV and HIV Stage 3 (AIDS) within the same year, allowing them to be counted in both the HIV incidence and HIV Stage 3 (AIDS) incidence tables.

### **DATA CONSIDERATIONS**

Data from 2024 is provisional. The enhanced HIV/AIDS Reporting System (eHARS) is a live database, and new information is entered as it is obtained. As such, counts, rates, and percentages provided in this report from 2022 and 2023 may vary from when initially reported in that year's Fast Facts.

Recent improvements in the timeliness of death ascertainment and national case deduplication efforts are reflected within this report's data. These efforts may be more apparent when comparing 2022, 2023, and 2024 Nevada HIV Fast Facts reports to previous iterations.

Due to changes in eHARS variables, data stratified by transgender status is not available in the 2024 Nevada HIV Fast Facts reports as it has been in previous years and is reported by sex assigned at birth only.

#### **TECHNICAL NOTES**

Per the Nevada Administrative Code (NAC) 441A.040, HIV is a reportable communicable disease as prescribed by NRS 441A.150, a diagnosis of HIV is reported to the local health authority by providers, medical facilities, and laboratories.



#### **VOCABULARY**

- Age Group is defined as the age of the individual at the time of the HIV and/or HIV Stage 3 (AIDS)
  diagnosis.
- All other counties include Carson City, Churchill, Douglas, Elko, Esmeralda, Eureka, Humboldt, Lander, Lincoln, Lyon, Mineral, Nye, Pershing, Storey, and White Pine Counties.
- Annual % Change is the percent increase or decrease relative to the number of cases in 2022.
   When interpreting data sets from small case counts, there may be a high variability.
- Column % is the percentage of the observations in the column's category.
- Female refers to persons assigned female at birth.
- Male refers to persons assigned male at birth.
- N is the total case count in the population.
- n (used for birth sex stratification) is the case count within a specific category (e.g., males).
- New HIV diagnoses are diagnoses counted in eHARS surveillance statistics and include HIV and HIV Stage 3 (AIDS) cases diagnosed in Nevada, both living and deceased. The surveillance data excludes HIV and HIV Stage 3 (AIDS) cases diagnosed in other states but currently living in Nevada.
- New HIV Stage 3 (AIDS) diagnoses are diagnoses counted in eHARS surveillance statistics and include HIV Stage 3 (AIDS) cases diagnosed in Nevada, both living and deceased. The Nevada 2022 HIV Fast Facts Page 3 of 22 surveillance data excludes HIV Stage 3 (AIDS) cases diagnosed in other states but currently living in Nevada.
- Persons living with HIV include data on persons living in Nevada with HIV (not yet HIV Stage 3
  (AIDS)) and HIV Stage 3 (AIDS) based on the current address listed in eHARS. These persons may or
  may not have been diagnosed with HIV or HIV Stage 3 (AIDS) in Nevada.
- Provisional data is data that is not yet complete and may be subject to revision as information continues to be collected and analyzed.
- Population is based on the 2024 population projections from the Nevada State Demographer vintage 2023 data.
- Rate is the number of cases per 100,000 persons and calculated by using the 2024 population projections from the Nevada State Demographer vintage 2023 data.



### **DATA TABLES**

Table 1. Nevada New HIV Diagnoses, 2024

		Total			Male			Female	
	N	Column %	Rate*	n	Column %	Rate*	n	Column %	Rate*
County of Diagnosis									
Clark	552	91%	22.6	477	92%	39.3	75	84%	6.1
Washoe	45	<b>7</b> %	8.6	31	6%	11.9	14	16%	5.4
All Other Counties**	8	1%	2.2	8	2%	4.3	0	0%	0.0
Total	605	100%	18.2	516	100%	31.1	89	100%	5.3
Race/Ethnicity									
White, non-Hispanic	128	21%	8.0	104	20%	13.0	24	27%	3.0
Black, non-Hispanic	145	24%	46.6	115	22%	73.5	30	34%	19.4
Hispanic	282	47%	26.9	252	49%	47.9	30	34%	5.8
Asian/Hawaiian/ Pacific Islander	36	6%	10.4	31	6%	19.5	5	6%	2.7
American Indian/ Alaska Native	3	0%	8.5	3	1%	17.4	0	0%	0.0
Multi-race/Other	11	2%	-	11	2%		0	0%	-
Total	605	100%	18.2	516	100%	31.1	89	100%	5.3
Age Group at Diagnosis	•								
< 13	1	0%	0.2	0	0%	0.0	1	1%	0.4
13 to 14	1	0%	1.2	1	0%	2.3	0	0%	0.0
15 to 19	14	2%	6.0	12	2%	10.1	2	2%	1.8
20 to 24	77	13%	32.7	68	13%	55.9	9	10%	7.9
25 to 29	101	17%	42.8	87	17%	72.0	14	16%	12.1
30 to 34	130	21%	54.0	118	23%	96.5	12	13%	10.1
35 to 39	111	18%	49.0	89	17%	77.5	22	25%	19.7
40 to 44	51	8%	23.9	43	8%	40.5	8	9%	7.5
45 to 54	67	11%	15.6	55	11%	25.5	12	13%	5.6
55 to 64	39	6%	9.7	35	<b>7</b> %	17.4	4	4%	2.0
65 +	13	2%	2.4	8	2%	3.3	5	6%	1.7
Total	605	100%	18.2	516	100%	31.1	89	100%	5.3
Transmission Category									
Male-to-male sexual contact (MSM)	375	62%	11.3	375	73%	22.6	0	0%	0.0
Injection drug use (IDU)	20	3%	0.6	14	3%	8.0	6	7%	0.4
MSM+IDU ,	25	4%	0.8	25	5%	1.5	0	0%	0.0
Heterosexual contact	46	8%	1.4	15	3%	0.9	31	35%	1.9
Perinatal exposure	1	0%	0.2	0	0%	0.0	1	1%	0.1
Transfusion/Hemophilia	0	0%	0.0	0	0%	0.0	0	0%	0.0
No identified risk (NIR)	138	23%	4.1	87	17%	16.9	51	57%	3.1
Total	605	100%	18.2	516	100%	31.1	89	100%	5.3

Source: Division of Public and Behavioral Health, HIV Reporting System (eHARS), (March 2025).

New HIV diagnoses are counted in eHARS surveillance statistics and include HIV and stage 3 (AIDS) cases diagnosed in Nevada, both living and deceased. The surveillance data excludes HIV/AIDS cases diagnosed in other states but who currently live in Nevada. HIV diagnoses and AIDS diagnoses may duplicate case counts if the person was diagnosed with both HIV and stage 3 (AIDS) in the same year.

<sup>\*</sup> Rates per 100,000 population were calculated using 2024 population projections from the Nevada State Demographer vintage 2023 data.

<sup>\*\*</sup>All other counties include Carson City, Churchill, Douglas, Elko, Esmeralda, Eureka, Humboldt, Lander, Lincoln, Lyon, Mineral, Nye, Pershing, Storey, and White Pine Counties.



Table 2. Nevada New HIV Stage 3 (AIDS) Diagnoses, 2024

		Total			Male			Female	
	Ν	Column %	Rate*	n	Column %	Rate*	n	Column %	Rate*
County of Diagnosis									
Clark	187	90%	7.7	157	90%	12.9	30	88%	2.4
Washoe	16	8%	3.1	12	<b>7</b> %	4.6	4	12%	1.5
All Other Counties**	5	2%	1.3	5	3%	2.7	0	0%	0.0
Total	208	100%	6.2	174	100%	10.5	34	100%	2.0
Race/Ethnicity									
White, non-Hispanic	56	27%	3.5	47	27%	5.9	9	26%	1.1
Black, non-Hispanic	57	27%	18.3	45	26%	28.8	12	35%	7.8
Hispanic	74	36%	7.1	65	37%	12.4	9	26%	1.7
Asian/Hawaiian/ Pacific Islander	11	5%	3.2	7	4%	4.4	4	12%	2.1
American Indian/ Alaska Native	1	0%	2.8	1	1%	5.8	0	0%	0.0
Multi-race/Other	9	4%	0.0	9	5%	0.0	0	0%	0.0
Total	208	100%	6.2	174	100%	10.5	34	100%	2.0
Age Group at Diagnosis									
< 13	0	0%	0.0	0	0%	0.0	0	0%	0.0
13 to 14	0	0%	0.0	0	0%	0.0	0	0%	0.0
15 to 19	3	1%	1.3	3	2%	2.5	0	0%	0.0
20 to 24	7	3%	3.0	4	2%	3.3	3	9%	2.6
25 to 29	14	<b>7</b> %	5.9	13	<b>7</b> %	10.8	1	3%	0.9
30 to 34	38	18%	15.8	34	20%	27.8	4	12%	3.4
35 to 39	41	20%	18.1	35	20%	30.5	6	18%	5.4
40 to 44	28	13%	13.1	25	14%	23.5	3	9%	2.8
45 to 54	43	21%	10.0	34	20%	15.7	9	26%	4.2
55 to 64	25	12%	6.2	20	11%	10.0	5	15%	2.5
65 +	9	4%	1.7	6	3%	2.5	3	9%	1.0
Total	208	100%	6.2	174	100%	10.5	34	100%	2.0
Transmission Category									
Male-to-male sexual contact (MSM)	114	55%	54.8	114	66%	6.9	0	0%	0.0
Injection drug use (IDU)	9	4%	4.3	5	3%	0.3	4	12%	0.2
MSM+IDU	8	4%	3.8	8	5%	0.5	0	0%	0.0
Heterosexual contact	21	10%	0.6	8	5%	0.5	13	38%	0.8
Perinatal exposure	0	0%	0.0	0	0%	0.0	0	0%	0.0
Transfusion/Hemophilia	0	0%	0.0	0	0%	0.0	0	0%	0.0
No identified risk (NIR)	56	27%	1.7	39	22%	2.3	17	50%	1.0
Total	208	100%	6.2	174	100%	10.5	34	100%	2.0
Source: Division of Dublic and Robavioral L	I a a lala	LIIV / Dava autina	C+	/ - L I A D	C) /\ /= == = \ 2021	-\			

New stage 3 (AIDS) diagnoses are counted in eHARS surveillance statistics and include stage 3 (AIDS) cases diagnosed in Nevada, both living and deceased. The surveillance data excludes AIDS cases diagnosed in other states but who currently live in Nevada.

<sup>\*</sup> Rates per 100,000 population were calculated using 2024 population projections from the Nevada State Demographer vintage 2023 data.

<sup>\*\*</sup>All other counties include Carson City, Churchill, Douglas, Elko, Esmeralda, Eureka, Humboldt, Lander, Lincoln, Lyon, Mineral, Nye, Pershing, Storey, and White Pine Counties.



Table 3. Persons Living with HIV§ in Nevada, 2024

		Total			Male			Female	
	N	Column %	Rate*	n	Column %	Rate*	n	Column %	Rate*
County of Residence									
Clark	12,570	87%	515.0	10,751	87%	885.6	1,819	86%	148.3
Washoe	1,314	9%	252.3	1,133	9%	434.3	181	9%	69.6
All Other Counties**	609	4%	163.9	484	4%	260.0	125	6%	67.4
Total	14,493	100%	434.8	12,368	100%	744.6	2,125	100%	127.1
Race/Ethnicity									
White, non-Hispanic	5,114	35%	320.9	4,502	36%	561.0	612	29%	77.3
Black, non-Hispanic	4,022	28%	1,293.1	3,056	25%	1,953.8	966	45%	624.8
Hispanic	4,253	29%	406.4	3,862	31%	734.5	391	18%	75.1
Asian/Hawaiian/ Pacific Islander	576	4%	166.4	496	4%	311.9	80	4%	42.8
American Indian/Alaska Native	71	0%	200.2	59	0%	343.1	12	1%	65.7
Multi-race/Other	455	3%	-	392	3%	-	63	3%	-
Unknown	2	0%	-	1	0%	-	1	0%	-
Total	14,493	100%	434.8	12,368	100%	744.6	2,125	100%	127.1
Age Group at End of Year									
< 13	9	0%	1.8	3	0%	1.2	6	0%	2.5
13 to 14	0	0%	-	0	0%	-	0	0%	-
15 to 19	31	0%	13.3	24	0%	20.1	7	0%	6.1
20 to 24	251	2%	106.5	217	2%	178.4	34	2%	29.8
25 to 29	818	6%	346.4	726	6%	601.0	92	4%	79.8
30 to 34	1,644	11%	682.6	1,500	12%	1,226.5	144	<b>7</b> %	121.5
35 to 39	1,889	13%	833.5	1,688	14%	1,470.5	201	9%	179.7
40 to 44	1,666	11%	782.3	1,428	12%	1,344.0	238	11%	223.0
45 to 54	2,845	20%	663.4	2,334	19%	1,080.8	511	24%	240.0
55 to 64	3,384	23%	839.0	2,839	23%	1,415.3	545	26%	268.8
65 +	1,956	13%	366.3	1,609	13%	663.0	347	16%	119.1
Unknown	0	0%	-	0	0%	-	0	0%	-
Total	14,493	100%	434.8	12,368	100%	744.6	2,125	100%	127.1
Transmission Category									
Male-to-male sexual contact (MSM)	9,371	65%	281.2	9,371	76%	564.2	0	0%	-
Injection drug use (IDU)	754	5%	22.6	472	4%	28.4	282	13%	16.9
MSM+IDU	831	6%	24.9	831	7%	50.0	0	0%	-
Heterosexual contact	1,430	10%	42.9	361	3%	21.7	1,069	50%	63.9
Perinatal exposure	86	1%	2.6	36	0%	2.2	50	2%	3.0
Transfusion/Hemophilia	6	0%	0.2	3	0%	0.2	3	0%	0.2
No identified risk (NIR)	2,015	14%	60.5	1,294	10%	77.9	721	34%	43.1
Total	14,493	100%		12,368	100%	744.6	2,125	100%	127.1
Source: Division of Dublic and Robavi							,	,	

§Persons Living with HIV indicate any person diagnosed with HIV regardless of HIV staging, including HIV stage 3 (AIDS), living in Nevada in 2024.

<sup>\*</sup> Rates per 100,000 population were calculated using 2024 population projections from the Nevada State Demographer vintage 2023 data.

<sup>\*\*</sup>All other counties include Carson City, Churchill, Douglas, Elko, Esmeralda, Eureka, Humboldt, Lander, Lincoln, Lyon, Mineral, Nye, Pershing, Storey, and White Pine Counties.



Table 4. Clark County New HIV diagnoses, 2024

	N	Total Column %	Rate*	n	Male Column %	Rate*	n	Female Column %	Rate*
Race/Ethnicity									
White, non-Hispanic	106	19%	10.5	88	18%	17.3	18	24%	3.6
Black, non-Hispanic	140	25%	48.2	113	24%	78.3	27	36%	18.4
Hispanic	260	<b>47</b> %	31.3	235	49%	56.5	25	33%	6.0
Asian/Hawaiian/ Pacific Islander	33	6%	11.1	28	6%	20.5	5	<b>7</b> %	3.1
American Indian/ Alaska Native	2	0%	13.0	2	0%	27.4	0	0%	0.0
Multi-race/Other	11	2%	0.0	11	2%	0.0	0	0%	0.0
Total	552	100%	22.6	477	100%	39.3	75	100%	6.1
Age Group at Diagnosis									
< 13	0	0%	0.0	0	0%	0.0	0	0%	0.0
13 to 14	1	0%	1.6	1	0%	3.1	0	0%	0.0
15 to 19	11	2%	6.3	11	2%	12.4	0	0%	0.0
20 to 24	66	12%	38.1	59	12%	66.7	7	9%	8.3
25 to 29	91	16%	51.9	79	17%	88.6	12	16%	13.9
30 to 34	122	22%	68.9	112	23%	125.0	10	13%	11.5
35 to 39	100	18%	60.3	82	17%	97.9	18	24%	22.0
40 to 44	50	9%	30.8	42	9%	52.1	8	11%	9.8
45 to 54	62	11%	19.0	50	10%	30.6	12	16%	7.4
55 to 64	37	<b>7</b> %	12.8	34	<b>7</b> %	23.5	3	4%	2.1
65 +	12	2%	3.3	7	1%	4.3	5	<b>7</b> %	2.5
Total	552	100%	22.6	477	100%	39.3	75	100%	6.1
Transmission Category									
Male-to-male sexual contact (MSM)	348	63%	14.3	348	73%	28.7	0	0%	0.0
Injection drug use (IDU)	17	3%	0.7	13	3%	1.1	4	5%	0.3
MSM+IDU	23	4%	0.9	23	5%	1.9	0	0%	0.0
Heterosexual contact	44	8%	1.8	14	3%	1.2	30	40%	2.4
Perinatal exposure	0	0%	0.0	0	0%	0.0	0	0%	0.0
Transfusion/Hemophilia	0	0%	0.0	0	0%	0.0	0	0%	0.0
No identified risk (NIR)	120	22%	4.9	79	17%	6.5	41	55%	3.3
Total	552	100%	22.6	477	100%	39.3	75	100%	6.1

New HIV diagnoses are counted in eHARS surveillance statistics and include HIV and stage 3 (AIDS) cases where resident county at time of diagnosis is Clark County, both living and deceased. The surveillance data excludes HIV/AIDS cases diagnosed in other states but who currently live in Clark County. HIV diagnoses and HIV stage 3 (AIDS) diagnoses may duplicate case counts if the person was diagnosed with both HIV and stage 3 (AIDS) in the same year.

<sup>\*</sup> Rates per 100,000 population were calculated using 2024 population projections from the Nevada State Demographer vintage 2023 data.



Table 5. Clark County New HIV Stage 3 (AIDS) Diagnoses, 2024

N   Column %   Rate*   n   Column %   n   Column %   Rate*   n   Column %   n   Column %   Rate*   n   Column %			Total			Male			Female	
Race/Ethnicity   White, non-Hispanic   45   24%   4.5   38   24%   7.4   7   23%   1.4		N		Rate*	n		Rate*	n		Rate*
Black, non-Hispanic	Race/Ethnicity									
Hispanic	White, non-Hispanic	45	24%	4.5	38	24%	7.4	7	23%	1.4
Asian/Hawaiian/ Pacific Islander	Black, non-Hispanic	54	29%	18.6	43	27%	29.8	11	37%	7.5
Islander	Hispanic	69	37%	8.3	61	39%	14.7	8	27%	1.9
Native         I         I%         6.5         I         I%         13.7         0         0%         0.0           Multi-race/Other         8         4%         -         8         5%         -         0         0%         -           Total         187         100%         7.7         157         100%         12.9         30         100%         2.4           Age Group at Diagnosis         -         0         0%         0.0         0         0%         0.0         0         0%         0.0           13 to 14         0         0%         0.0         0         0%         0.0         0         0%         0.0           15 to 19         3         2%         1.7         3         2%         3.4         0         0%         0.0           20 to 24         6         3%         3.5         4         3%         4.5         2         7%         2.4           25 to 29         13         7%         7.4         12         8%         13.5         1         3%         1.2           30 to 34         35         19%         19.8         31         20%         34.6         4         13% <td></td> <td>10</td> <td>5%</td> <td>3.4</td> <td>6</td> <td>4%</td> <td>4.4</td> <td>4</td> <td>13%</td> <td>2.5</td>		10	5%	3.4	6	4%	4.4	4	13%	2.5
Total         187         100%         7.7         157         100%         12.9         30         100%         2.4           Age Group at Diagnosis         Color of the property	•	1	1%	6.5	1	1%	13.7	0	0%	0.0
Age Group at Diagnosis  <13	Multi-race/Other	8	4%	-	8	5%	-	0	0%	-
<13	Total	187	100%	7.7	157	100%	12.9	30	100%	2.4
13 to 14         0         0%         0.0         0         0%         0.0         0         0%         0.0           15 to 19         3         2%         1.7         3         2%         3.4         0         0%         0.0           20 to 24         6         3%         3.5         4         3%         4.5         2         7%         2.4           25 to 29         13         7%         7.4         12         8%         13.5         1         3%         1.2           30 to 34         35         19%         19.8         31         20%         34.6         4         13%         4.6           35 to 39         34         18%         20.5         29         18%         34.6         5         17%         6.1           40 to 44         26         14%         16.0         23         15%         28.5         3         10%         3.5           45 to 54         39         21%         11.9         30         19%         18.3         9         30%         5.5           55 to 64         23         12%         7.9         19         12%         13.1         4         13%         2	Age Group at Diagnosis									
15 to 19	< 13	0	0%	0.0	0	0%	0.0	0	0%	0.0
20 to 24         6         3%         3.5         4         3%         4.5         2         7%         2.4           25 to 29         13         7%         7.4         12         8%         13.5         1         3%         1.2           30 to 34         35         19%         19.8         31         20%         34.6         4         13%         4.6           35 to 39         34         18%         20.5         29         18%         34.6         5         17%         6.1           40 to 44         26         14%         16.0         23         15%         28.5         3         10%         3.7           45 to 54         39         21%         11.9         30         19%         18.3         9         30%         5.5           55 to 64         23         12%         7.9         19         12%         13.1         4         13%         2.7           65 +         8         4%         2.2         6         4%         3.6         2         7%         1.0           Total         187         100%         7.7         157         100%         12.9         30         100%	13 to 14		0%	0.0	0	0%	0.0	0	0%	0.0
25 to 29         13         7%         7.4         12         8%         13.5         1         3%         1.2           30 to 34         35         19%         19.8         31         20%         34.6         4         13%         4.6           35 to 39         34         18%         20.5         29         18%         34.6         5         17%         6.1           40 to 44         26         14%         16.0         23         15%         28.5         3         10%         3.7           45 to 54         39         21%         11.9         30         19%         18.3         9         30%         5.5           55 to 64         23         12%         7.9         19         12%         13.1         4         13%         2.7           65 +         8         4%         2.2         6         4%         3.6         2         7%         1.0           Total         187         100%         7.7         157         100%         12.9         30         100%         2.4           Transmission Category         Male-to-male sexual contact (MSM)         104         66%         8.6         0         <	15 to 19	3	2%	1.7	3	2%	3.4	0	0%	0.0
30 to 34         35         19%         19.8         31         20%         34.6         4         13%         4.6           35 to 39         34         18%         20.5         29         18%         34.6         5         17%         6.1           40 to 44         26         14%         16.0         23         15%         28.5         3         10%         3.7           45 to 54         39         21%         11.9         30         19%         18.3         9         30%         5.5           55 to 64         23         12%         7.9         19         12%         13.1         4         13%         2.7           65 +         8         4%         2.2         6         4%         3.6         2         7%         1.0           Total         187         100%         7.7         157         100%         12.9         30         100%         2.4           Transmission Category           Male-to-male sexual contact (MSM)         104         56%         4.3         104         66%         8.6         0         0%         0.0           Injection drug use (IDU)         8         4%         0.	20 to 24	6	3%	3.5	4	3%	4.5	2	<b>7</b> %	2.4
35 to 39         34         18%         20.5         29         18%         34.6         5         17%         6.1           40 to 44         26         14%         16.0         23         15%         28.5         3         10%         3.7           45 to 54         39         21%         11.9         30         19%         18.3         9         30%         5.5           55 to 64         23         12%         7.9         19         12%         13.1         4         13%         2.7           65 +         8         4%         2.2         6         4%         3.6         2         7%         1.0           Total         187         100%         7.7         157         100%         12.9         30         100%         2.4           Transmission Category           Male-to-male sexual contact (MSM)         104         56%         4.3         104         66%         8.6         0         0%         0.0           Injection drug use (IDU)         8         4%         0.3         4         3%         0.3         4         13%         0.3           MSM+IDU         7         4%         0.3	25 to 29			7.4		8%	13.5	1	3%	1.2
40 to 44         26         14%         16.0         23         15%         28.5         3         10%         3.7           45 to 54         39         21%         11.9         30         19%         18.3         9         30%         5.5           55 to 64         23         12%         7.9         19         12%         13.1         4         13%         2.7           65 +         8         4%         2.2         6         4%         3.6         2         7%         1.0           Total         187         100%         7.7         157         100%         12.9         30         100%         2.4           Transmission Category         Male-to-male sexual contact (MSM)         104         56%         4.3         104         66%         8.6         0         0%         0.0           Injection drug use (IDU)         8         4%         0.3         4         3%         0.3         4         13%         0.3           MSM+IDU         7         4%         0.3         7         4%         0.6         0         0%         0.0           Heterosexual contact         19         10%         0.8	30 to 34		19%	19.8	31	20%	34.6	4	13%	4.6
45 to 54         39         21%         11.9         30         19%         18.3         9         30%         5.5           55 to 64         23         12%         7.9         19         12%         13.1         4         13%         2.7           65 +         8         4%         2.2         6         4%         3.6         2         7%         1.0           Total         187         100%         7.7         157         100%         12.9         30         100%         2.4           Transmission Category           Male-to-male sexual contact (MSM)         104         56%         4.3         104         66%         8.6         0         0%         0.0           Injection drug use (IDU)         8         4%         0.3         4         3%         0.3         4         13%         0.3           MSM+IDU         7         4%         0.3         7         4%         0.6         0         0%         0.0           Heterosexual contact         19         10%         0.8         7         4%         0.6         12         40%         1.0           Perinatal exposure         0         0%         <		34	18%	20.5	29	18%	34.6	5	<b>17</b> %	6.1
55 to 64         23         12%         7.9         19         12%         13.1         4         13%         2.7           65 +         8         4%         2.2         6         4%         3.6         2         7%         1.0           Total         187         100%         7.7         157         100%         12.9         30         100%         2.4           Transmission Category           Male-to-male sexual contact (MSM)         104         56%         4.3         104         66%         8.6         0         0%         0.0           Injection drug use (IDU)         8         4%         0.3         4         3%         0.3         4         13%         0.3           MSM+IDU         7         4%         0.3         7         4%         0.6         0         0%         0.0           Heterosexual contact         19         10%         0.8         7         4%         0.6         12         40%         1.0           Perinatal exposure         0         0%         0.0         0         0%         0.0         0         0%         0.0           No identified risk (NIR)         49         26% <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>28.5</td> <td>3</td> <td></td> <td></td>							28.5	3		
65 +         8         4%         2.2         6         4%         3.6         2         7%         1.0           Total         187         100%         7.7         157         100%         12.9         30         100%         2.4           Transmission Category           Male-to-male sexual contact (MSM)         104         56%         4.3         104         66%         8.6         0         0%         0.0           Injection drug use (IDU)         8         4%         0.3         4         3%         0.3         4         13%         0.3           MSM+IDU         7         4%         0.3         7         4%         0.6         0         0%         0.0           Heterosexual contact         19         10%         0.8         7         4%         0.6         12         40%         1.0           Perinatal exposure         0         0%         0.0         0         0%         0.0         0         0         0%         0.0           Transfusion/ Hemophilia         0         0%         0.0         0         0%         0.0         0         0%         0.0           No identified risk (NIR) <td< td=""><td>45 to 54</td><td>39</td><td>21%</td><td>11.9</td><td>30</td><td>19%</td><td>18.3</td><td>9</td><td>30%</td><td>5.5</td></td<>	45 to 54	39	21%	11.9	30	19%	18.3	9	30%	5.5
Total         187         100%         7.7         157         100%         12.9         30         100%         2.4           Transmission Category         Male-to-male sexual contact (MSM)         104         56%         4.3         104         66%         8.6         0         0%         0.0           Injection drug use (IDU)         8         4%         0.3         4         3%         0.3         4         13%         0.3           MSM+IDU         7         4%         0.3         7         4%         0.6         0         0%         0.0           Heterosexual contact         19         10%         0.8         7         4%         0.6         12         40%         1.0           Perinatal exposure         0         0%         0.0         0         0%         0.0         0         0%         0.0           Transfusion/ Hemophilia         0         0%         0.0         0         0%         0.0         0         0%         0.0           No identified risk (NIR)         49         26%         2.0         35         22%         2.9         14         47%         1.1							13.1			
Transmission Category           Male-to-male sexual contact (MSM)         104         56%         4.3         104         66%         8.6         0         0%         0.0           Injection drug use (IDU)         8         4%         0.3         4         3%         0.3         4         13%         0.3           MSM+IDU         7         4%         0.3         7         4%         0.6         0         0%         0.0           Heterosexual contact         19         10%         0.8         7         4%         0.6         12         40%         1.0           Perinatal exposure         0         0%         0.0         0         0%         0.0         0         0%         0.0           Transfusion/ Hemophilia         0         0%         0.0         0         0%         0.0         0         0%         0.0           No identified risk (NIR)         49         26%         2.0         35         22%         2.9         14         47%         1.1	65 +		4%	2.2	6	4%	3.6		<b>7</b> %	1.0
Male-to-male sexual contact (MSM)         104         56%         4.3         104         66%         8.6         0         0%         0.0           Injection drug use (IDU)         8         4%         0.3         4         3%         0.3         4         13%         0.3           MSM+IDU         7         4%         0.3         7         4%         0.6         0         0%         0.0           Heterosexual contact         19         10%         0.8         7         4%         0.6         12         40%         1.0           Perinatal exposure         0         0%         0.0         0         0%         0.0         0         0%         0.0           Transfusion/ Hemophilia         0         0%         0.0         0         0%         0.0         0         0%         0.0           No identified risk (NIR)         49         26%         2.0         35         22%         2.9         14         47%         1.1	Total	187	100%	7.7	157	100%	12.9	30	100%	2.4
contact (MSM)         104         56%         4.3         104         66%         8.6         0         0%         0.0           Injection drug use (IDU)         8         4%         0.3         4         3%         0.3         4         13%         0.3           MSM+IDU         7         4%         0.3         7         4%         0.6         0         0%         0.0           Heterosexual contact         19         10%         0.8         7         4%         0.6         12         40%         1.0           Perinatal exposure         0         0%         0.0         0         0%         0.0         0         0%         0.0           Transfusion/ Hemophilia         0         0%         0.0         0         0%         0.0         0         0%         0.0           No identified risk (NIR)         49         26%         2.0         35         22%         2.9         14         47%         1.1	Transmission Category									
MSM+IDU         7         4%         0.3         7         4%         0.6         0         0%         0.0           Heterosexual contact         19         10%         0.8         7         4%         0.6         12         40%         1.0           Perinatal exposure         0         0%         0.0         0         0%         0.0         0         0%         0.0           Transfusion/ Hemophilia         0         0%         0.0         0         0%         0.0         0         0%         0.0           No identified risk (NIR)         49         26%         2.0         35         22%         2.9         14         47%         1.1		104	56%	4.3	104	66%	8.6	0	0%	0.0
Heterosexual contact         19         10%         0.8         7         4%         0.6         12         40%         1.0           Perinatal exposure         0         0%         0.0         0         0%         0.0         0         0%         0.0           Transfusion/ Hemophilia         0         0%         0.0         0         0%         0.0         0         0%         0.0           No identified risk (NIR)         49         26%         2.0         35         22%         2.9         14         47%         1.1	Injection drug use (IDU)	8	4%	0.3	4	3%	0.3	4	13%	0.3
Perinatal exposure         0         0%         0.0         0         0%         0.0         0         0%         0.0           Transfusion/ Hemophilia         0         0%         0.0         0         0%         0.0         0         0%         0.0           No identified risk (NIR)         49         26%         2.0         35         22%         2.9         14         47%         1.1		7	4%	0.3		4%	0.6	0	0%	0.0
Transfusion/ Hemophilia         0         0%         0.0         0         0%         0.0         0         0%         0.0           No identified risk (NIR)         49         26%         2.0         35         22%         2.9         14         47%         1.1	Heterosexual contact	19	10%	0.8	7		0.6	12		1.0
No identified risk (NIR) 49 26% 2.0 35 22% 2.9 14 47% 1.1	Perinatal exposure	_		0.0	0		0.0			0.0
` '	Transfusion/ Hemophilia	0	0%	0.0	0	0%	0.0	0	0%	0.0
Total 187 100% 7.7 157 100% 12.9 30 100% 2.4	No identified risk (NIR)	49	26%	2.0	35	22%	2.9	14	47%	1.1
	Total	187	100%	7.7	157	100%	12.9	30	100%	2.4

New stage 3 (AIDS) diagnoses are counted in eHARS surveillance statistics and include stage 3 (AIDS) cases diagnosed in Clark County, both living and deceased. The surveillance data excludes AIDS cases diagnosed in other states but who currently live in Clark County.

<sup>\*</sup> Rates per 100,000 population were calculated using 2024 population projections from the Nevada State Demographer vintage 2023 data.



Table 6. Persons Living with HIV§ in Clark County, 2024

White, non-Hispanic         4,028         32%         400.2         3,580         33%         701.8         448         25%         90.3           Black, non-Hispanic         3,821         30%         1,314.7         2,903         27%         2,012.3         918         50%         627.2           Hispanic         3,747         30%         450.9         3,427         32%         824.6         320         18%         77.0           Asian/Hawaiian/ Pacific Islander         533         4%         179.4         461         4%         337.4         72         4%         44.9           American Indian/ Alaska Native         53         0%         345.4         44         0%         601.7         9         0%         112.0           Multi-race/Other         388         3%         -         336         3%         -         52         3%         -           Total         12,570         100%         515.0         10,751         100%         885.6         1,819         100         148.3           Age Group at End of Year         2         3         0%         1.6         5         0%         2.7           13 to 14         0         0         -			Total			Male			Female	
White, non-Hispanic         4,028         32%         400.2         3,580         33%         701.8         448         25%         90.3           Black, non-Hispanic         3,821         30%         1,314.7         2,903         27%         2,012.3         918         50%         627.2           Hispanic         3,747         30%         450.9         3,427         32%         824.6         320         18%         77.0           Asian/Hawaiian/ Pacific Islander         533         4%         179.4         461         4%         337.4         72         4%         44.9           American Indian/ Alaska Native         53         0%         345.4         44         0%         601.7         9         0%         112.0           Multi-race/Other         388         3%         -         336         3%         -         52         3%         -           Total         12,570         100%         515.0         10,751         100%         885.6         1,819         100         148.3           Age Group at End of Year         2         3         0%         1.6         5         0%         2.7           13 to 14         0         0         -		N	Column %	Rate*	n	Column %	Rate*	n	Column %	Rate*
Black, non-Hispanic   3,821   30%   1,314.7   2,903   27%   2,012.3   918   50%   627.2   Hispanic   3,747   30%   450.9   3,427   32%   824.6   320   18%   77.0   Asian/Hawaiian/ Pacific Islander   533   4%   179.4   461   4%   337.4   72   4%   44.9   American Indian/ Alaska   53   0%   345.4   44   0%   601.7   9   0%   112.0   Multi-race/Other   388   3%   -     336   3%   -     52   3%     -   Total   12,570   100%   515.0   10,751   100%   885.6   1,819   100%   148.3   Age Group at End of Year   -	Race/Ethnicity									
Hispanic   3,747   30%   450.9   3,427   32%   824.6   320   18%   77.0   Asian/Hawaiian/ Pacific   533   4%   179.4   461   4%   337.4   72   4%   44.9   44.9   American Indian/ Alaska   53   0%   345.4   44   0%   601.7   9   0%   112.0   112	White, non-Hispanic	4,028	32%	400.2	3,580	33%	701.8	448	25%	90.3
Asian/Hawaiian/ Pacific Islander  American Indian/ Alaska Native  Multi-race/Other 388 3% - 336 3% - 52 3% - 510 10.0 10.0 10.0 10.0 10.0 10.0 10.0	Black, non-Hispanic	3,821	30%	1,314.7	2,903	27%	2,012.3	918	50%	627.2
Islander	Hispanic	3,747	30%	450.9	3,427	32%	824.6	320	18%	77.0
Slander	Asian/Hawaiian/ Pacific	<b>577</b>	7.0/	170 /	7.61	7.0/	777 /	72	7.0/	/, /, Q
Native		333	470	179.4	401	470	337.4	12	470	44.9
Native Multi-race/Other 388 3% - 336 3% - 52 3% - Total 12,570 100% 515.0 10,751 100% 885.6 1,819 100% 148.3  Age Group at End of Year  < 13 8 0% 2.2 3 0% 1.6 5 0% 2.7  13 to 14 0 0 0% - 0 0% - 0 0% 519.0 15.0 15.0 15.0 19 28 0% 16.1 23 0% 25.8 5 0% 5.9  20 to 24 222 2% 128.2 197 2% 222.8 25 1% 29.5 25 to 29 72.4 6% 412.9 645 6% 723.6 79 4% 91.6 30 to 34 1,473 12% 832.4 1,345 13% 1,500.5 128 7% 146.6 30 to 34 1,673 12% 832.4 1,345 13% 1,500.5 128 7% 146.6 30 to 34 1,688 13% 1,018.7 1,515 14% 1,807.9 173 100% 211.2 40 to 44 1,502 12% 924.3 1,297 12% 1,609.7 205 11% 250.2 45 to 54 2,488 20% 761.9 2,036 19% 1,244.4 452 25% 277.4 55 to 64 2,839 23% 979.0 2,390 22% 1,653.8 449 25% 308.6 65 + 1,598 13% 441.2 1,300 12% 790.5 298 16% 150.7 Unknown 0 0 0% - 0 0% - 0 0% - 0 0 0% - 7 o 0 0 0% - 7 o 0 0% - 7 o 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	American Indian/ Alaska	53	0%	3/15/	44	0%	601.7	a	0%	112 0
Total   12,570   100%   515.0   10,751   100%   885.6   1,819   100%   148.3    Age Group at End of Year	Native			5-5			001.7			112.0
Age Group at End of Year  < 13 8 0% 2.2 3 0% 1.6 5 0% 2.7 13 to 14 0 0 0% - 0 0% - 0 0% - 0 0% 5.9 15 to 19 28 0% 16.1 23 0% 25.8 5 0% 5.9 20 to 24 222 2% 128.2 197 2% 222.8 25 1% 29.5 25 to 29 724 6% 412.9 645 6% 723.6 79 4% 91.6 30 to 34 1,473 12% 832.4 1,345 13% 1,500.5 128 7% 146.6 35 to 39 1,688 13% 1,018.7 1,515 14% 1,807.9 173 10% 211.2 40 to 44 1,502 12% 924.3 1,297 12% 1,609.7 205 11% 250.2 45 to 54 2,488 20% 761.9 2,036 19% 1,244.4 452 25% 277.4 55 to 64 2,839 23% 979.0 2,390 22% 1,653.8 449 25% 308.6 65 + 1,598 13% 441.2 1,300 12% 790.5 298 16% 150.7 Unknown 0 0 0% - 0 0% - 0 0% - 0 0% - 7 Total 12,570 100% 515.0 10,751 100% 885.6 1,819 100% 148.3 Transmission Category Male-to-male sexual contact (MSM) Injection drug use (IDU) 576 5% 23.6 370 3% 30.5 206 11% 16.8 MSM+IDU 641 5% 26.3 641 6% 52.8 0 0% - Heterosexual contact 1,264 10% 518. 315 3% 25.9 949 52% 77.4 Transfusion/Hemophilia 4 0% 0.2 2 0% 0.2 2 0% 0.2 2 0% 0.2 No identified risk (NIR) 1,672 13% 68.5 1,050 10% 86.5 622 34% 50.7	Multi-race/Other			-			-			-
<13		12,570	100%	515.0	10,751	100%	885.6	1,819	100%	148.3
13 to 14	Age Group at End of Year									
15 to 19         28         0%         16.1         23         0%         25.8         5         0%         5.9           20 to 24         222         2%         128.2         197         2%         222.8         25         1%         29.5           25 to 29         724         6%         412.9         645         6%         723.6         79         4%         91.6           30 to 34         1,473         12%         832.4         1,345         13%         1,500.5         128         7%         146.6           35 to 39         1,668         13%         1,018.7         1,515         14%         1,807.9         173         10%         211.2           40 to 44         1,502         12%         924.3         1,297         12%         1,609.7         205         11%         250.2           45 to 54         2,488         20%         761.9         2,036         19%         1,244.4         452         25%         277.4           45 to 54         2,488         20%         761.9         2,390         22%         1,653.8         449         25%         308.6           65 +         1,598         13%         441.2         1,30				2.2			1.6	-		2.7
20 to 24         222         2%         128.2         197         2%         222.8         25         1%         29.5           25 to 29         724         6%         412.9         645         6%         723.6         79         4%         91.6           30 to 34         1,473         12%         832.4         1,345         13%         1,500.5         128         7%         146.6           35 to 39         1,688         13%         1,018.7         1,515         14%         1,807.9         173         10%         211.2           40 to 44         1,502         12%         924.3         1,297         12%         1,609.7         205         11%         250.2           45 to 54         2,488         20%         761.9         2,036         19%         1,244.4         452         25%         277.4           45 to 54         2,488         20%         761.9         2,036         19%         1,244.4         452         25%         277.8           55 to 64         2,839         23%         979.0         2,390         22%         1,653.8         449         25%         308.6           65 +         1,598         13%         441.2	13 to 14			-	-		-	-		-
25 to 29         724         6%         412.9         645         6%         723.6         79         4%         91.6           30 to 34         1,473         12%         832.4         1,345         13%         1,500.5         128         7%         146.6           35 to 39         1,688         13%         1,018.7         1,515         14%         1,807.9         173         10%         211.2           40 to 44         1,502         12%         924.3         1,297         12%         1,609.7         205         11%         250.2           45 to 54         2,488         20%         761.9         2,036         19%         1,244.4         452         25%         277.4           55 to 64         2,839         23%         979.0         2,390         22%         1,653.8         449         25%         308.6           65 +         1,598         13%         441.2         1,300         12%         790.5         298         16%         150.7           Unknown         0         0%         -         0         0%         -         0         0%         -         0         0%         -         0         0%         -         15										5.9
30 to 34         1,473         12%         832.4         1,345         13%         1,500.5         128         7%         146.6           35 to 39         1,688         13%         1,018.7         1,515         14%         1,807.9         173         10%         211.2           40 to 44         1,502         12%         924.3         1,297         12%         1,609.7         205         11%         250.2           45 to 54         2,488         20%         761.9         2,036         19%         1,244.4         452         25%         277.4           55 to 64         2,839         23%         979.0         2,390         22%         1,653.8         449         25%         308.6           65 +         1,598         13%         441.2         1,300         12%         790.5         298         16%         150.7           Unknown         0         0%         -         0         0%         -         0         0%         -           Total         12,570         100%         515.0         10,751         100%         885.6         1,819         100%         148.3           Transmission Category         Male-to-male sexual contact (MSM)				128.2						
35 to 39         1,688         13%         1,018.7         1,515         14%         1,807.9         173         10%         211.2           40 to 44         1,502         12%         924.3         1,297         12%         1,609.7         205         11%         250.2           45 to 54         2,488         20%         761.9         2,036         19%         1,244.4         452         25%         277.4           55 to 64         2,839         23%         979.0         2,390         22%         1,653.8         449         25%         308.6           65 +         1,598         13%         441.2         1,300         12%         790.5         298         16%         150.7           Unknown         0         0%         -         0         0%         -         0         0%         -           Total         12,570         100%         515.0         10,751         100%         885.6         1,819         100%         148.3           Transmission Category         Male-to-male sexual contact (MSM)         8,340         66%         341.7         8,340         78%         687.0         0         0%         -         -         -         -		724		412.9			723.6			
40 to 44         1,502         12%         924.3         1,297         12%         1,609.7         205         11%         250.2           45 to 54         2,488         20%         761.9         2,036         19%         1,244.4         452         25%         277.4           55 to 64         2,839         23%         979.0         2,390         22%         1,653.8         449         25%         308.6           65 +         1,598         13%         441.2         1,300         12%         790.5         298         16%         150.7           Unknown         0         0%         -         0         0%         -         0         0%         -           Total         12,570         100%         515.0         10,751         100%         885.6         1,819         100%         148.3           Transmission Category         Male-to-male sexual contact (MSM)         8,340         66%         341.7         8,340         78%         687.0         0         0%         -         -         0         0%         -         -         -         -         0         0%         -         -         -         0         0%         -         -	30 to 34	1,473		832.4	1,345		1,500.5	128		146.6
45 to 54       2,488       20%       761.9       2,036       19%       1,244.4       452       25%       277.4         55 to 64       2,839       23%       979.0       2,390       22%       1,653.8       449       25%       308.6         65 +       1,598       13%       441.2       1,300       12%       790.5       298       16%       150.7         Unknown       0       0%       -       0       0%       -       0       0%       -         Total       12,570       100%       515.0       10,751       100%       885.6       1,819       100%       148.3         Transmission Category       Male-to-male sexual contact (MSM)       8,340       66%       341.7       8,340       78%       687.0       0       0%       -         Injection drug use (IDU)       576       5%       23.6       370       3%       30.5       206       11%       16.8         MSM+IDU       641       5%       26.3       641       6%       52.8       0       0%       -         Heterosexual contact       1,264       10%       51.8       315       3%       25.9       949       52%	35 to 39	1,688	13%	1,018.7	1,515	14%	1,807.9	173	10%	211.2
55 to 64         2,839         23%         979.0         2,390         22%         1,653.8         449         25%         308.6           65 +         1,598         13%         441.2         1,300         12%         790.5         298         16%         150.7           Unknown         0         0%         -         0         0%         -         0         0%         -           Total         12,570         100%         515.0         10,751         100%         885.6         1,819         100%         148.3           Transmission Category         Male-to-male sexual contact (MSM)         8,340         66%         341.7         8,340         78%         687.0         0         0%         -         -         0         0%         -         -         0         0%         -         -         0         0%         -         -         0         0%         -         -         0         0%         -         -         0         0%         -         -         -         0         0%         -         -         0         0%         -         -         0         0%         -         -         0         0%         -	40 to 44		12%	924.3	1,297		1,609.7	205	11%	250.2
1,598   13%   441.2   1,300   12%   790.5   298   16%   150.7	45 to 54	2,488	20%	761.9	2,036	19%	1,244.4	452	25%	277.4
Unknown         0         0%         -         0         0%         -         0         0%         -         0         0%         -         0         0%         -         0         0%         -         0         0%         -         10         0%         -         10         0%         -         10         0%         148.3           Transmission Category         Male-to-male sexual contact (MSM)         8,340         66%         341.7         8,340         78%         687.0         0         0%         -         -         0         0%         -         -         0         0%         -         -         0         0%         -         -         0         0%         -         -         0         0%         -         -         0         0%         -         -         0         0%         -         -         0         0%         -         -         0         0%         -         -         0         0%         -         -         0         0%         -         -         0         0         -         0         0         -         0         0         -         0         0         0		2,839		979.0	2,390	22%	1,653.8	449		308.6
Total         12,570         100%         515.0         10,751         100%         885.6         1,819         100%         148.3           Transmission Category         Male-to-male sexual contact (MSM)         8,340         66%         341.7         8,340         78%         687.0         0         0%         -           Injection drug use (IDU)         576         5%         23.6         370         3%         30.5         206         11%         16.8           MSM+IDU         641         5%         26.3         641         6%         52.8         0         0%         -           Heterosexual contact         1,264         10%         51.8         315         3%         25.9         949         52%         77.4           Perinatal exposure         73         1%         3.0         33         0%         2.7         40         2%         3.3           Transfusion/Hemophilia         4         0%         0.2         2         0%         0.2         2         0%         0.2           No identified risk (NIR)         1,672         13%         68.5         1,050         10%         86.5         622         34%         50.7	65 +	1,598		441.2	1,300		790.5	298	16%	150.7
Transmission Category           Male-to-male sexual contact (MSM)         8,340         66%         341.7         8,340         78%         687.0         0         0%         -           Injection drug use (IDU)         576         5%         23.6         370         3%         30.5         206         11%         16.8           MSM+IDU         641         5%         26.3         641         6%         52.8         0         0%         -           Heterosexual contact         1,264         10%         51.8         315         3%         25.9         949         52%         77.4           Perinatal exposure         73         1%         3.0         33         0%         2.7         40         2%         3.3           Transfusion/Hemophilia         4         0%         0.2         2         0%         0.2         2         0%         0.2           No identified risk (NIR)         1,672         13%         68.5         1,050         10%         86.5         622         34%         50.7	Unknown	0	0%	-	0	0%	-	0	0%	-
Male-to-male sexual contact (MSM)         8,340         66%         341.7         8,340         78%         687.0         0         0%         -           Injection drug use (IDU)         576         5%         23.6         370         3%         30.5         206         11%         16.8           MSM+IDU         641         5%         26.3         641         6%         52.8         0         0%         -           Heterosexual contact         1,264         10%         51.8         315         3%         25.9         949         52%         77.4           Perinatal exposure         73         1%         3.0         33         0%         2.7         40         2%         3.3           Transfusion/Hemophilia         4         0%         0.2         2         0%         0.2         2         0%         0.2           No identified risk (NIR)         1,672         13%         68.5         1,050         10%         86.5         622         34%         50.7	Total	12,570	100%	515.0	10,751	100%	885.6	1,819	100%	148.3
contact (MSM)         8,340         66%         341.7         8,340         78%         687.0         0         0%         -           Injection drug use (IDU)         576         5%         23.6         370         3%         30.5         206         11%         16.8           MSM+IDU         641         5%         26.3         641         6%         52.8         0         0%         -           Heterosexual contact         1,264         10%         51.8         315         3%         25.9         949         52%         77.4           Perinatal exposure         73         1%         3.0         33         0%         2.7         40         2%         3.3           Transfusion/Hemophilia         4         0%         0.2         2         0%         0.2         2         0%         0.2           No identified risk (NIR)         1,672         13%         68.5         1,050         10%         86.5         622         34%         50.7	Transmission Category									
Injection drug use (IDU) 576 5% 23.6 370 3% 30.5 206 11% 16.8 MSM+IDU 641 5% 26.3 641 6% 52.8 0 0% - Heterosexual contact 1,264 10% 51.8 315 3% 25.9 949 52% 77.4 Perinatal exposure 73 1% 3.0 33 0% 2.7 40 2% 3.3 Transfusion/Hemophilia 4 0% 0.2 2 0% 0.2 2 0% 0.2 No identified risk (NIR) 1,672 13% 68.5 1,050 10% 86.5 622 34% 50.7	Male-to-male sexual	0.7/0	660/	7/17	07/0	700/	607.0	0	00/	
MSM+IDU         641         5%         26.3         641         6%         52.8         0         0%         -           Heterosexual contact         1,264         10%         51.8         315         3%         25.9         949         52%         77.4           Perinatal exposure         73         1%         3.0         33         0%         2.7         40         2%         3.3           Transfusion/Hemophilia         4         0%         0.2         2         0%         0.2         2         0%         0.2           No identified risk (NIR)         1,672         13%         68.5         1,050         10%         86.5         622         34%         50.7	contact (MSM)	0,340	00%	341.7	0,340	70%	667.0	U	0%	-
Heterosexual contact         1,264         10%         51.8         315         3%         25.9         949         52%         77.4           Perinatal exposure         73         1%         3.0         33         0%         2.7         40         2%         3.3           Transfusion/Hemophilia         4         0%         0.2         2         0%         0.2         2         0%         0.2           No identified risk (NIR)         1,672         13%         68.5         1,050         10%         86.5         622         34%         50.7	Injection drug use (IDU)	576	5%	23.6	370	3%	30.5	206	11%	16.8
Perinatal exposure         73         1%         3.0         33         0%         2.7         40         2%         3.3           Transfusion/Hemophilia         4         0%         0.2         2         0%         0.2         2         0%         0.2           No identified risk (NIR)         1,672         13%         68.5         1,050         10%         86.5         622         34%         50.7	MSM+IDU	641	5%	26.3	641		52.8	0	0%	-
Transfusion/Hemophilia         4         0%         0.2         2         0%         0.2         2         0%         0.2           No identified risk (NIR)         1,672         13%         68.5         1,050         10%         86.5         622         34%         50.7	Heterosexual contact	1,264	10%	51.8	315	3%	25.9	949	52%	77.4
No identified risk (NIR) 1,672 13% 68.5 1,050 10% 86.5 622 34% 50.7	Perinatal exposure	73	1%	3.0	33	0%	2.7	40	2%	3.3
	Transfusion/Hemophilia		0%		2	0%	0.2	2		0.2
Total 12,570 100% 515.0 10,751 100% 885.6 1,819 100% 148.3	No identified risk (NIR)	1,672	13%	68.5	1,050	10%	86.5	622	34%	50.7
	Total	12,570	100%	515.0	10,751	100%	885.6	1,819	100%	148.3

Persons living with HIV data include data on persons living in Nevada with HIV (not yet stage 3 (AIDS)) and stage 3 (AIDS) based on the current address listed in the HIV/AIDS Reporting System (eHARS). These persons may or may not have been diagnosed with HIV or stage 3 (AIDS) in Clark County or Nevada.

§Persons Living with HIV indicate any person diagnosed with HIV regardless of HIV staging, including HIV stage 3 (AIDS), living in Clark County in 2024.

<sup>\*</sup> Rates per 100,000 population were calculated using 2024 population projections from the Nevada State Demographer vintage 2023 data.



**Table 7. Washoe County New HIV Diagnoses, 2024** 

		Total			Male			Female	
	N	Column %	Rate*	n	Column %	Rate*	n	Column %	Rate*
Race/Ethnicity									
White, non-Hispanic	19	42%	6.1	13	42%	8.2	6	43%	3.9
Black, non-Hispanic	5	11%	35.0	2	6%	25.1	3	21%	47.6
Hispanic	18	40%	12.4	13	42%	17.8	5	36%	6.9
Asian/Hawaiian/ Pacific Islander	3	<b>7</b> %	7.4	3	10%	16.0	0	0%	0.0
American Indian/ Alaska Native	0	0%	0.0	0	0%	0.0	0	0%	0.0
Multi-race/Other	0	0%	-	0	0%	-	0	0%	-
Total	45	100%	8.6	31	100%	11.9	14	100%	5.4
Age Group at Diagnosis									
< 13	1	2%	1.3	0	0%	0.0	1	<b>7</b> %	2.7
13 to 14	0	0%	0.0	0	0%	0.0	0	0%	0.0
15 to 19	3	<b>7</b> %	8.2	1	3%	5.3	2	14%	11.2
20 to 24	10	22%	23.3	8	26%	36.5	2	14%	9.5
25 to 29	7	16%	18.6	5	16%	25.5	2	14%	11.1
30 to 34	8	18%	22.9	6	19%	34.6	2	14%	11.4
35 to 39	10	22%	28.3	6	19%	34.1	4	29%	22.6
40 to 44	1	2%	3.0	1	3%	6.0	0	0%	0.0
45 to 54	3	<b>7</b> %	5.0	3	10%	9.9	0	0%	0.0
55 to 64	1	2%	1.6	0	0%	0.0	1	<b>7</b> %	3.1
65 +	1	2%	1.1	1	3%	2.4	0	0%	0.0
Total	45	100%	8.6	31	100%	11.9	14	100%	5.4
Transmission Category									
Male-to-male sexual contact (MSM)	25	56%	4.8	25	81%	9.6	0	0%	0.0
Injection drug use (IDU)	3	7%	0.6	1	3%	0.4	2	14%	8.0
MSM+IDU	2	4%	0.4	2	6%	8.0	0	0%	0.0
Heterosexual contact	1	2%	0.2	0	0%	0.0	1	<b>7</b> %	0.4
Perinatal exposure	1	2%	0.2	0	0%	0.0	1	<b>7</b> %	0.4
Transfusion/Hemophilia	0	0%	0.0	0	0%	0.0	0	0%	0.0
No identified risk (NIR)	13	29%	2.5	3	10%	1.2	10	71%	3.8
Total	45	100%	8.6	31	100%	11.9	14	100%	5.4
Source: Division of Public and Reha		Haalth IIIV/Dar	ortina Cva	+	LIADC\ /March	2025/			

New HIV diagnoses are counted in eHARS surveillance statistics and include HIV and stage 3 (AIDS) cases where resident county at time of diagnosis is Washoe County, both living and deceased. The surveillance data excludes HIV/AIDS cases diagnosed in other states but who currently live in Washoe County. HIV diagnoses and HIV stage 3 (AIDS) diagnoses may duplicate case counts if the person was diagnosed with both HIV and stage 3 (AIDS) in the same year.

<sup>\*</sup> Rates per 100,000 population were calculated using 2024 population projections from the Nevada State Demographer vintage 2023 data.



Table 8. Washoe County New Stage 3 (AIDS) Diagnoses, 2024

		Total			Male			Female	
	Ν	Column %	Rate*	n	Column %	Rate*	n	Column %	Rate*
Race/Ethnicity									
White, non-Hispanic	8	50%	2.6	6	50%	3.8	2	50%	1.3
Black, non-Hispanic	2	13%	14.0	1	8%	12.5	1	25%	15.9
Hispanic	4	25%	2.7	3	25%	4.1	1	25%	1.4
Asian/Hawaiian/ Pacific Islander	1	6%	2.5	1	8%	5.3	0	0%	0.0
American Indian/ Alaska Native	0	0%	0.0	0	0%	0.0	0	0%	0.0
Multi-race/Other	1	6%	-	1	8%	-	0	0%	-
Total	16	100%	3.1	12	100%	4.6	4	100%	1.5
Age Group at Diagnosis									
< 13	0	0%	0.0	0	0%	0.0	0	0%	0.0
13 to 14	0	0%	0.0	0	0%	0.0	0	0%	0.0
15 to 19	0	0%	0.0	0	0%	0.0	0	0%	0.0
20 to 24	1	6%	2.3	0	0%	0.0	1	25%	4.8
25 to 29	0	0%	0.0	0	0%	0.0	0	0%	0.0
30 to 34	3	19%	8.6	3	25%	17.3	0	0%	0.0
35 to 39	7	44%	19.8	6	50%	34.1	1	25%	5.7
40 to 44	0	0%	0.0	0	0%	0.0	0	0%	0.0
45 to 54	3	19%	5.0	3	25%	9.9	0	0%	0.0
55 to 64	1	6%	1.6	0	0%	0.0	1	25%	3.1
65 +	1	6%	1.1	0	0%	0.0	1	25%	2.1
Total	16	100%	3.1	12	100%	4.6	4	100%	1.5
Transmission Category									
Male-to-male sexual contact (MSM)	9	56%	1.7	9	75%	3.5	0	0%	0.0
Injection drug use (IDU)	1	6%	0.2	1	8%	0.4	0	0%	0.0
MSM+IDU	1	6%	0.2	1	8%	0.4	0	0%	0.0
Heterosexual contact	1	6%	0.2	0	0%	0.0	1	25%	0.4
Perinatal exposure	0	0%	0.0	0	0%	0.0	0	0%	0.0
Transfusion/ Hemophilia	0	0%	0.0	0	0%	0.0	0	0%	0.0
No identified risk (NIR)	4	25%	0.8	1	8%	0.4	3	75%	1.2
Total	16	100%	3.1	12	100%	4.6	4	100%	1.5

New stage 3 (AIDS) diagnoses are counted in eHARS surveillance statistics and include stage 3 (AIDS) cases where resident county at time of diagnosis is Washoe County. The surveillance data excludes AIDS cases diagnosed in other states but who currently live in Washoe County.

<sup>\*</sup> Rates per 100,000 population were calculated using 2024 population projections from the Nevada State Demographer vintage 2023 data.



Table 9. Persons Living with HIV§ in Washoe County, 2024

	Total				Male		Female			
	Ν	Column %	Rate*	n	Column %	Rate*	n	Column %	Rate*	
Race/Ethnicity										
White, non-Hispanic	730	56%	232.7	638	56%	404.1	92	51%	59.1	
Black, non-Hispanic	133	10%	930.9	101	9%	1,265.2	32	18%	507.6	
Hispanic	356	27%	244.4	314	28%	429.0	42	23%	57.9	
Asian/Hawaiian/ Pacific Islander	34	3%	83.7	28	2%	149.5	6	3%	27.4	
American Indian/ Alaska Native	8	1%	122.9	6	1%	195.3	2	1%	58.2	
Multi-race/Other	52	4%	0.0	45	4%	0.0	7	4%	-	
Unknown	1	0%	0.0	1	0%	0.0	0	0%	-	
Total	1,314	100%	252.3	1,133	100%	434.3	181	100%	69.6	
Age Group at End of Year										
< 13	1	0%	1.3	0	0%	0.0	1	1%	2.7	
13 to 14	0	0%	0.0	0	0%	0.0	0	0%	0.0	
15 to 19	3	0%	8.2	1	0%	5.3	2	1%	11.2	
20 to 24	21	2%	48.9	14	1%	63.8	7	4%	33.3	
25 to 29	78	6%	207.3	68	6%	347.3	10	6%	55.4	
30 to 34	127	10%	363.8	118	10%	680.0	9	5%	51.3	
35 to 39	139	11%	394.0	122	11%	693.6	17	9%	96.1	
40 to 44	121	9%	364.4	95	8%	570.9	26	14%	156.9	
45 to 54	241	18%	403.3	209	18%	689.2	32	18%	108.7	
55 to 64	354	27%	561.8	300	26%	961.9	54	30%	169.7	
65 +	229	17%	260.9	206	18%	503.8	23	13%	49.1	
Unknown	0	0%	0.0	0	0%	-	0	0%	0.0	
Total	1,314	100%	252.3	1,133	100%	434.3	181	100%	69.6	
Transmission Category										
Male-to-male sexual contact (MSM)	774	59%	148.6	774	68%	296.7	0	0%	0.0	
Injection drug use (IDU)	91	<b>7</b> %	17.5	52	5%	19.9	39	22%	15.0	
MSM+IDU	130	10%	25.0	130	11%	49.8	0	0%	0.0	
Heterosexual contact	96	<b>7</b> %	18.4	29	3%	11.1	67	37%	25.8	
Perinatal exposure	6	0%	1.2	1	0%	0.4	5	3%	1.9	
Transfusion/Hemophilia	1	0%	0.2	0	0%	0.0	1	1%	0.4	
No identified risk (NIR)	216	16%	41.5	147	13%	56.4	69	38%	26.5	
Total	1,314	100%	252.3	1,133	100%	434.3	181	100%	69.6	

Persons living with HIV data include data on persons living in Washoe County with HIV (not yet stage 3 (AIDS)) and stage 3 (AIDS) based on the current address listed in the HIV/AIDS Reporting System (eHARS). These persons may or may not have been diagnosed with HIV or stage 3 (AIDS) in Washoe County or Nevada.

§Persons Living with HIV indicate any person diagnosed with HIV regardless of HIV staging, including HIV stage 3 (AIDS), living in Washoe County in 2024.

<sup>\*</sup> Rates per 100,000 population were calculated using 2024 population projections from the Nevada State Demographer vintage 2023 data.



Table 10. All Other Counties New HIV Diagnoses, 2024

		Total			Male			Female	
	N	Column %	Rate*	n	Column %	Rate*	n	Column %	Rate*
Race/Ethnicity									
White, non-Hispanic	3	38%	1.1	3	38%	2.2	0	-	0.0
Black, non-Hispanic	0	0%	0.0	0	0%	0.0	0	-	0.0
Hispanic	4	50%	5.7	4	50%	10.8	0	-	0.0
Asian/Hawaiian/ Pacific Islander	0	0%	0.0	0	0%	0.0	0	-	0.0
American Indian/ Alaska Native	1	13%	7.3	1	13%	14.7	0	-	0.0
Multi-race/Other	0	0%	0.0	0	0%	0.0	0	-	0.0
Total	8	100%	2.2	8	100%	4.3	0	0%	0.0
Age Group at Diagnosis									
< 13	0	0%	0.0	0	0%	0.0	0	-	0.0
13 to 14	0	0%	0.0	0	0%	0.0	0	-	0.0
15 to 19	0	0%	0.0	0	0%	0.0	0	-	0.0
20 to 24	1	13%	5.1	1	13%	8.9	0	-	0.0
25 to 29	3	38%	13.0	3	38%	24.9	0	-	0.0
30 to 34	0	0%	0.0	0	0%	0.0	0	-	0.0
35 to 39	1	13%	3.9	1	13%	7.5	0	-	0.0
40 to 44	0	0%	0.0	0	0%	0.0	0	-	0.0
45 to 54	2	25%	4.7	2	25%	9.1	0	-	0.0
55 to 64	1	13%	2.0	1	13%	4.0	0	-	0.0
65 +	0	0%	0.0	0	0%	0.0	0	-	0.0
Total	8	100%	2.2	8	100%	4.3	0	0%	0.0
Transmission Category									
Male-to-male sexual contact (MSM)	2	25%	0.5	2	25%	1.1	0	-	0.0
Injection drug use (IDU)	0	0%	0.0	0	0%	0.0	0	-	0.0
MSM+IDU	0	0%	0.0	0	0%	0.0	0	-	0.0
Heterosexual contact	1	13%	0.3	1	13%	0.5	0	-	0.0
Perinatal exposure	0	0%	0.0	0	0%	0.0	0	-	0.0
Transfusion/Hemophilia	0	0%	0.0	0	0%	0.0	0	-	0.0
No identified risk (NIR)	5	63%	1.3	5	63%	2.7	0	-	0.0
Total	8	100%	2.2	8	100%	4.3	0	0%	0.0

New HIV diagnoses are counted in eHARS surveillance statistics and include HIV and stage 3 (AIDS) cases where resident county at time of diagnosis is All Other Counties, both living and deceased. The surveillance data excludes HIV/AIDS cases diagnosed in other states but who currently live in All Other Counties. HIV diagnoses and HIV stage 3 (AIDS) diagnoses may duplicate case counts if the person was diagnosed with both HIV and stage 3 (AIDS) in the same year.

^All other counties include Carson City, Churchill, Douglas, Elko, Esmeralda, Eureka, Humboldt, Lander, Lincoln, Lyon, Mineral, Nye, Pershing, Storey, and White Pine Counties.

<sup>\*</sup> Rates per 100,000 population were calculated using 2024 population projections from the Nevada State Demographer vintage 2023 data.



Table 11. All Other Counties \ New HIV Stage 3 (AIDS) Diagnoses, 2024

		Total			Male			Female		
	N	Column %	Rate*	n	Column %	Rate*	n	Column %	Rate*	
Race/Ethnicity										
White, non-Hispanic	3	60%	1.1	3	60%	2.2	0	-	0.0	
Black, non-Hispanic	1	20%	16.4	1	20%	24.0	0	-	0.0	
Hispanic	1	20%	1.4	1	20%	2.7	0	-	0.0	
Asian/Hawaiian/ Pacific Islander	0	0%	0.0	0	0%	0.0	0	-	0.0	
American Indian/ Alaska Native	0	0%	0.0	0	0%	0.0	0	-	0.0	
Multi-race/Other	0	0%	0.0	0	0%	0.0	0	-	0.0	
Total	5	100%	1.3	5	100%	2.7	0	0%	0.0	
Age Group at Diagnosis										
< 13	0	0%	0.0	0	0%	0.0	0	-	0.0	
13 to 14	0	0%	0.0	0	0%	0.0	0	-	0.0	
15 to 19	0	0%	0.0	0	0%	0.0	0	-	0.0	
20 to 24	0	0%	0.0	0	0%	0.0	0	-	0.0	
25 to 29	1	20%	4.3	1	20%	8.3	0	-	0.0	
30 to 34	0	0%	0.0	0	0%	0.0	0	-	0.0	
35 to 39	0	0%	0.0	0	0%	0.0	0	-	0.0	
40 to 44	2	40%	11.6	2	40%	22.1	0	-	0.0	
45 to 54	1	20%	2.4	1	20%	4.5	0	-	0.0	
55 to 64	1	20%	2.0	1	20%	4.0	0	-	0.0	
65 +	0	0%	0.0	0	0%	0.0	0	-	0.0	
Total	5	100%	1.3	5	100%	2.7	0	0%	0.0	
Transmission Category										
Male-to-male sexual contact (MSM)	1	20%	0.3	1	20%	0.5	0	-	0.0	
Injection drug use (IDU)	0	0%	0.0	0	0%	0.0	0	-	0.0	
MSM+IDU	0	0%	0.0	0	0%	0.0	0	-	0.0	
Heterosexual contact	1	20%	0.3	1	20%	0.5	0	-	0.0	
Perinatal exposure	0	0%	0.0	0	0%	0.0	0	-	0.0	
Transfusion/ Hemophilia	0	0%	0.0	0	0%	0.0	0	-	0.0	
No identified risk (NIR)	3	60%	8.0	3	60%	1.6	0	-	0.0	
Total	5	100%	1.3	5	100%	2.7	0	0%	0.0	

New stage 3 (AIDS) diagnoses are counted in eHARS surveillance statistics and include stage 3 (AIDS) cases where resident county at time of diagnosis is AII Other Counties. The surveillance data excludes AIDS cases diagnosed in other states but who currently live in AII Other Counties.

^All other counties include Carson City, Churchill, Douglas, Elko, Esmeralda, Eureka, Humboldt, Lander, Lincoln, Lyon, Mineral, Nye, Pershing, Storey, and White Pine Counties.

<sup>\*</sup> Rates per 100,000 population were calculated using 2024 population projections from the Nevada State Demographer vintage 2023 data.



Table 12. Persons Living with HIV§ in All Other Counties^, 2024

N   Race/Ethnicity   White, non-Hispanic   356   Black, non-Hispanic   150   Asian/Hawaiian/ Pacific   Islander   American Indian/ Alaska   Native   Multi-race/Other   15   Unknown   1   Total   609   Age Group at End of Year   < 13   0   13 to 14   0   15 to 19   0   20 to 24   25 to 29   16	2% 0% 100%	130.1 1,113.6 214.8 107.4 73.4	284 52 121 7	59% 11% 25% 1%	211.2 1,248.2 326.9 189.9	72 16 29	58% 13% 0%	51.7 824.7 88.4
White, non-Hispanic       356         Black, non-Hispanic       68         Hispanic       150         Asian/Hawaiian/ Pacific       9         Islander       9         American Indian/ Alaska       10         Multi-race/Other       15         Unknown       1         Total       609         Age Group at End of Year         < 13       0         13 to 14       0         15 to 19       0         20 to 24       8         25 to 29       16	11% 25% 1% 2% 2% 0%	1,113.6 214.8 107.4	52 121 7	11% 25%	1,248.2 326.9	16 29	13%	824.7
Black, non-Hispanic       68         Hispanic       150         Asian/Hawaiian/ Pacific       9         Islander       10         American Indian/ Alaska       10         Multi-race/Other       15         Unknown       1         Total       609         Age Group at End of Year         < 13	11% 25% 1% 2% 2% 0%	1,113.6 214.8 107.4	52 121 7	11% 25%	1,248.2 326.9	16 29	13%	824.7
Hispanic       150         Asian/Hawaiian/ Pacific       9         Islander       10         American Indian/ Alaska       10         Multi-race/Other       15         Unknown       1         Total       609         Age Group at End of Year         < 13	25% 1% 2% 2% 0%	214.8	121 7	25%	326.9	29		
Asian/Hawaiian/ Pacific Islander  American Indian/ Alaska Native  Multi-race/Other 15  Unknown 1  Total 609  Age Group at End of Year  < 13 0  13 to 14 0  15 to 19 0  20 to 24 8  25 to 29 16	1% 2% 2% 0%	107.4	7				0%	00 /
Islander   9	2% 2% 0%			1%	189.9	2		00.4
Native     IO       Multi-race/Other     15       Unknown     1       Total     609       Age Group at End of Year     < 13	2% 0%	73.4	9			_	2%	42.6
Unknown     1       Total     609       Age Group at End of Year     < 13	0%	-		2%	132.1	1	1%	14.7
Total 609  Age Group at End of Year  < 13 0  13 to 14 0  15 to 19 0  20 to 24 8  25 to 29 16			11	2%	-	4	3%	-
Age Group at End of Year < 13 0 13 to 14 0 15 to 19 0 20 to 24 8 25 to 29 16	100%	-	0	0%	-	1	1%	-
< 13 0 13 to 14 0 15 to 19 0 20 to 24 8 25 to 29 16		163.9	484	100%	260.0	125	<b>77</b> %	67.4
13 to 14 0 15 to 19 0 20 to 24 8 25 to 29 16								
15 to 19 0 20 to 24 8 25 to 29 16	0%	0.0	0	0%	0.0	0	0%	0.0
20 to 24 8 25 to 29 16	0%	0.0	0	0%	0.0	0	0%	0.0
25 to 29 16	0%	0.0	0	0%	0.0	0	0%	0.0
	1%	40.6	6	1%	53.4	2	2%	23.6
	3%	69.1	13	3%	107.7	3	2%	27.1
30 to 34 44	<b>7</b> %	151.8	37	8%	241.7	7	6%	51.2
35 to 39 62	10%	241.7	51	11%	380.5	11	9%	89.8
40 to 44 43	<b>7</b> %	249.0	36	7%	398.6	7	6%	85.0
45 to 54 116	19%	272.6	89	18%	404.3	27	22%	131.5
55 to 64 191	31%	379.5	149	31%	598.7	42	34%	165.1
65 + 129	21%	153.4	103	21%	275.8	26	21%	55.6
Unknown 0	0%	-	0	0%	-	0	0%	-
Total 609	100%	163.9	484	100%	260.0	125	100%	67.4
Transmission Category								
Male-to-male sexual contact (MSM) 257	42%	69.1	257	53%	138.1	0	0%	-
Injection drug use (IDU) 87	14%	23.4	50	10%	26.9	37	30%	19.9
MSM+IDU 60	10%	16.1	60	12%	32.2	0	0%	-
Heterosexual contact 70	11%	18.8	17	4%	9.1	53	42%	28.6
Perinatal exposure 7	1%	1.9	2	0%	1.1	5	4%	2.7
Transfusion/Hemophilia 1	0%	0.3	1	0%	0.5	0	0%	-
No identified risk (NIR) 127	21%	34.2	97	20%	52.1	30	24%	16.2
Total 609	<b>~1</b> /U	163.9			~_··	50	<u>~</u> F/U	10.2

Persons living with HIV data include data on persons living in All Other Counties with HIV (not yet stage 3 (AIDS)) and stage 3 (AIDS) based on the current address listed in the HIV/AIDS Reporting System (eHARS). These persons may or may not have been diagnosed with HIV or stage 3 (AIDS) in All Other Counties or Nevada.

§Persons Living with HIV indicate any person diagnosed with HIV regardless of HIV staging, including HIV stage 3 (AIDS), living in Nevada in 2024.

<sup>^</sup>All other counties include Carson City, Churchill, Douglas, Elko, Esmeralda, Eureka, Humboldt, Lander, Lincoln, Lyon, Mineral, Nye, Pershing, Storey, and White Pine Counties.

<sup>\*</sup> Rates per 100,000 population were calculated using 2024 population projections from the Nevada State Demographer vintage 2023 data.



Table 13. Annual Percent Change: New HIV Diagnoses, Nevada, 2022-2024

	2022		2023		2024		Annual %	
	N	Column %	N	Column %	N	Column %	Changei	
County								
Clark	485	89%	513	88%	552	91%	14%	
Washoe	38	7%	50	9%	45	<b>7</b> %	18%	
All Other Counties**	20	4%	18	3%	8	1%	-60%	
Total	543	100%	581	100%	605	100%	11%	
Sex at Birth								
Male	455	84%	510	88%	516	85%	13%	
Female	88	16%	71	12%	89	15%	1%	
Total	543	100%	581	100%	605	100%	11%	
Race/Ethnicity								
White, non-Hispanic	126	23%	146	25%	128	21%	2%	
Black, non-Hispanic	149	27%	147	25%	145	24%	-3%	
Hispanic	228	42%	235	40%	282	47%	24%	
Asian/Hawaiian/Pacific Islander	18	3%	29	5%	36	6%	100%	
American Indian/Alaska Native	3	1%	6	1%	3	0%	0%	
Multi-race/Other	19	3%	18	3%	11	2%	-42%	
Total	543	100%	581	100%	605	100%	11%	
Age Group*								
< 13	2	0%	1	0%	1	0%	0%	
13 to 14	0	0%	0	0%	1	0%	0%	
15 to 19	14	3%	17	3%	14	2%	0%	
20 to 24	74	14%	65	11%	77	13%	4%	
25 to 29	103	19%	106	18%	101	17%	-2%	
30 to 34	100	18%	109	19%	130	21%	30%	
35 to 39	84	15%	81	14%	111	18%	32%	
40 to 44	57	10%	68	12%	51	8%	-11%	
45 to 54	65	12%	73	13%	67	11%	3%	
55 to 64	34	6%	48	8%	39	6%	15%	
65 +	10	2%	13	2%	13	2%	30%	
Total	543	100%	581	100%	605	100%	11%	
Transmission Category								
Males								
Male-to-male sexual contact (MSM)	311	57%	347	60%	375	62%	21%	
IDU	12	2%	8	1%	14	2%	17%	
MSM+IDU	25	5%	35	6%	25	4%	0%	
Heterosexual contact	8	1%	11	2%	15	2%	88%	
Perinatal Exposure	1	0%	1	0%	0	0%	0%	
No identified risk (NIR)	98	18%	108	19%	87	14%	-11%	
Subtotal	455	84%	510	88%	516	85%	13%	
Females								
IDU	10	2%	8	1%	6	1%	-40%	
Heterosexual contact	20	4%	18	3%	31	5%	55%	
Perinatal Exposure	0	0%	1	0%	1	0%	0%	
No identified risk (NIR)	58	11%	44	8%	51	8%	-12%	
Subtotal	88	16%	71	12%	89	15%	1%	
Total	543	100%	581	100%	605	100%	11%	

 ${\it i}$ Annual % Change is the percentage increase or decrease relative to the number of cases in 2022.

<sup>\*</sup> For New HIV diagnoses, age refers to age at HIV infection diagnosis. For persons living with HIV, age refers to age at the end of the report year.

<sup>\*\*</sup>All other counties include Carson City, Churchill, Douglas, Elko, Esmeralda, Eureka, Humboldt, Lander, Lincoln, Lyon, Mineral, Nye, Pershing, Storey, and White Pine Counties.



Table 14. Annual Percent Change: Persons Living with HIV§ in Nevada, 2022-2024

	2022		2023		2024	Annual %	
	N	Column %	N	Column %	N	Column %	Change
County	•						
Clark	11,463	87%	11,975	87%	12,570	87%	10%
Washoe	1,213	9%	1,257	9%	1,314	9%	8%
All Other Counties**	, 551	4%	571	4%	609	4%	11%
Total	13,227	100%	13,803	100%	14,493	100%	10%
Sex at Birth	<u> </u>	<u>.</u>	·		,	<u>.                                    </u>	
Male	11,254	85%	11,752	85%	12,368	85%	10%
Female	1,973	15%	2,051	15%	2,125	15%	8%
Total	13,227	100%	13,803	100%	14,493	100%	10%
Race/Ethnicity					,		
White, non-Hispanic	4,967	38%	5,038	36%	5,114	35%	3%
Black, non-Hispanic	3,718	28%	3,854	28%	4,022	28%	8%
Hispanic	3,605	27%	3,870	28%	4,253	29%	18%
Asian/Hawaiian/Pacific Islander	506	4%	538	4%	576	4%	14%
American Indian/Alaska Native	65	0%	71	1%	71	0%	9%
Multi-race/Other	364	3%	430	3%	455	3%	25%
Unknown	2	0%	2	0%	2	0%	0%
Total	13,227	100%	13,803	100%	14,493	100%	10%
Age Group*			·		·	·	
< 13	7	0%	8	0%	9	0%	29%
13 to 14	2	0%	1	0%	0	0%	-100%
15 to 19	37	0%	36	0%	31	0%	-16%
20 to 24	255	2%	251	2%	251	2%	-2%
25 to 29	843	6%	798	6%	818	6%	-3%
30 to 34	1,559	12%	1,610	12%	1,644	11%	5%
35 to 39	1,603	12%	1,730	13%	1,889	13%	18%
40 to 44	1,433	11%	1,542	11%	1,666	11%	16%
45 to 54	2,856	22%	2,813	20%	2,845	20%	0%
55 to 64	3,131	24%	3,279	24%	3,384	23%	8%
65 +	1,501	11%	1,735	13%	1,956	13%	30%
Total	13,227	100%	13,803	100%	14,493	100%	10%
Transmission Category							
Males							
Male-to-male sexual contact (MSM)	8,494	64%	8,901	64%	9,371	65%	10%
IDU	470	4%	477	3%	472	3%	0%
MSM+IDU	771	6%	814	6%	831	6%	8%
Heterosexual contact	345	3%	354	3%	361	2%	5%
Perinatal Exposure	35	0%	35	0%	36	0%	3%
Transfusion/Hemophilia	3	0%	3	0%	3	0%	0%
No identified risk (NIR)	1,136	9%	1,168	8%	1,294	9%	14%
Subtotal	11,254	85%	11,752	85%	12,368	85%	10%
Females							
IDU	269	2%	284	2%	282	2%	5%
Heterosexual contact	1,017	8%	1,044	8%	1,069	<b>7</b> %	5%
Perinatal Exposure	50	0%	51	0%	50	0%	0%
Transfusion/Hemophilia	3	0%	3	0%	3	0%	0%
No identified risk (NIR)	634	5%	669	5%	721	5%	14%
Subtotal	1,973	15%	2,051	15%	2,125	15%	8%
Total	13,227	100%	13,803	100%	14,493	100%	10%

§Persons living HIV data includes data on persons living in Nevada with HIV (any stage) in 2024, regardless of place of diagnosis.

 ${\it i}$ Annual % Change is the percentage increase or decrease relative to the number of cases in 2022.

<sup>\*\*</sup>All other counties include Carson City, Churchill, Douglas, Elko, Esmeralda, Eureka, Humboldt, Lander, Lincoln, Lyon, Mineral, Nye, Pershing, Storey, and White Pine Counties.



Table 15 Facility of Diagnosis for New HIV Diagnoses, Nevada, 2024

	Nevada		Clark	County	Washo	e County	All Other	Counties*
	N	Column %	n	Column %	n	Column %	n	Column %
Facility of Diagnosis		/0		70		70		70
Missing	62	10.2%	46	8.3%	8	17.8%	8	100.0%
Facility/Other	2	0.3%	1	0.2%	1	2.2%	0	0.0%
Facility/Unknown	3	0.5%	2	0.4%	1	2.2%	0	0.0%
Inpatient Facility/Hospital	33	5.5%	32	5.8%	1	2.2%	0	0.0%
Outpatient Facility	12	2.0%	12	2.2%	0	0.0%	0	0.0%
Outpatient Facility/Private Physician's Office	233	38.5%	228	41.3%	5	11.1%	0	0.0%
Outpatient Facility/Adult HIV Clinic	19	3.1%	8	1.4%	11	24.4%	0	0.0%
Outpatient Facility/TB Clinic	9	1.5%	9	1.6%	0	0.0%	0	0.0%
Outpatient Facility/Other Clinic	23	3.8%	19	3.4%	4	8.9%	0	0.0%
Outpatient Facility/Community Health Center	2	0.3%	2	0.4%	0	0.0%	0	0.0%
Outpatient Facility/Primary Care Clinic, Not Specified	1	0.2%	1	0.2%	0	0.0%	0	0.0%
Outpatient Facility/Unknown	51	8.4%	51	9.2%	0	0.0%	0	0.0%
Emergency Room	4	0.7%	3	0.5%	1	2.2%	0	0.0%
(S,D,R) Blood Bank or Plasma Center	12	2.0%	7	1.3%	5	11.1%	0	0.0%
(S,D,R) HIV Counseling and Testing Site	16	2.6%	9	1.6%	7	15.6%	0	0.0%
(S,D,R) STD Clinic	57	9.4%	57	10.3%	0	0.0%	0	0.0%
Laboratory	8	1.3%	8	1.4%	0	0.0%	0	0.0%
Other Specific Facility	36	6.0%	36	6.5%	0	0.0%	0	0.0%
Other Specific Facility/Correctional Facility	16	2.6%	15	2.7%	1	2.2%	0	0.0%
Other Specific Facility/Coroner or Medical Examiner	6	1.0%	6	1.1%	0	0.0%	0	0.0%
Total	605	100.0%	552	100.0%	45	100.0%	8	100.0%

New HIV Diagnoses are counted in eHARS surveillance statistics and include HIV and stage 3 (AIDS) cases diagnosed in Nevada, both living and deceased. The surveillance data excludes HIV cases diagnosed in other states, but who currently live in Nevada. HIV diagnoses and stage 3 (AIDS) diagnoses may duplicate case counts if the person was diagnosed with both HIV and stage 3 (AIDS) in 2024.

<sup>\*</sup>All other counties include Carson City, Churchill, Douglas, Elko, Esmeralda, Eureka, Humboldt, Lander, Lincoln, Lyon, Mineral, Nye, Pershing, Storey, and White Pine Counties.



Table 16. Facility of Diagnosis for New Stage 3 (AIDS) Diagnoses, Nevada HIV, 2024

	Nevada		Clar	k County	Washo	e County	All Other	Counties
	N	Column %	n	Column %	n	Column %	n	Column %
Facility of Diagnosis								
Missing	56	26.9%	49	26.2%	5	31.3%	2	40.0%
Facility/Other	3	1.4%	1	0.5%	1	6.3%	1	20.0%
Inpatient Facility/Hospital	23	11.1%	17	9.1%	6	37.5%	0	0.0%
Outpatient Facility	1	0.5%	1	0.5%	0	0.0%	0	0.0%
Outpatient Facility/Private Physician's Office	66	31.7%	65	34.8%	1	6.3%	0	0.0%
Outpatient Facility/Adult HIV Clinic	5	2.4%	3	1.6%	1	6.3%	1	20.0%
Outpatient Facility/TB Clinic	5	2.4%	5	2.7%	0	0.0%	0	0.0%
Outpatient Facility/Other Clinic	14	6.7%	13	7.0%	1	6.3%	0	0.0%
Outpatient Facility/Unknown	7	3.4%	7	3.7%	0	0.0%	0	0.0%
(S,D,R) HIV Counseling and Testing Site	3	1.4%	2	1.1%	1	6.3%	0	0.0%
(S,D,R) STD Clinic	9	4.3%	9	4.8%	0	0.0%	0	0.0%
Other Specific Facility	5	2.4%	5	2.7%	0	0.0%	0	0.0%
Other Specific Facility/Correctional Facility	7	3.4%	6	3.2%	0	0.0%	1	20.0%
Other Specific Facility/Coroner or Medical Examiner	4	1.9%	4	2.1%	0	0.0%	0	0.0%
Total	208	100.0%	187	100.0%	16	100.0%	5	100.0%

New AIDS Diagnoses are counted in eHARS surveillance statistics and include stage 3 (AIDS) cases diagnosed in Nevada, both living and deceased. The surveillance data excludes AIDS cases diagnosed in other states, but who currently live in Nevada.

\*All other counties include Carson City, Churchill, Douglas, Elko, Esmeralda, Eureka, Humboldt, Lander, Lincoln, Lyon, Mineral, Nye, Pershing, Storey, and White Pine Counties.



#### For more information contact:

Lyell S. Collins, MBA

HIV Prevention and Surveillance Program Manager (Health Program Specialist II) Prevention and Surveillance Program, Office of HIV Nevada department of Health and Human Services Community Health Services 2290 S Jones Suite 100, Las Vegas, NV, 89146

Email: lscollins@health.nv.gov

Phone: (702) 486-8105

Ted Ariaga, MS

HIV/STD Biostatistician (Health Resource Analyst II) Office of Analytics Nevada Department of Health and Human Services Division of Public and Behavioral Health 4126 Technology Way Ste 201, Carson City, NV, 89706

Email: tartiaga@nvha.nv.gov

Phone: (775) 684-5953

Scarlett Cazares, MPH

HIV Surveillance Epidemiologist (Health Resource Analyst II) Prevention and Surveillance Program, Office of HIV Nevada Department of Health and Human Services Division of Public and Behavioral Health Community Health Services 10375 Professional Circle Ste 341, Reno, NV, 89521

Email: scazares@health.nv.gov

Phone: (775) 688-0453

Recommended Citation: State of Nevada, Office of HIV. Division of Public and Behavioral Health. 2024 HIV Fast Facts. Las Vegas, Nevada. el.O. July 2025.

#### Additional References:

1) End HIV Nevada 2) HIV OPHIE 3) HIV Prevention Program 4) Office of Analytics

This publication was supported by the Centers for Disease Control and Prevention (CDC) through Grant Number NU62PS924828-02 for the HIV Prevention and Surveillance Program. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Nevada State Department of Health and Human Services nor the Centers for Disease Control and Prevention.





